Acute and Long-Term Adverse Effects of Antipsychotics

Antipsychotics have become the cornerstone of management for many severe mental disorders. Primarily developed for the treatment of schizophrenia, several antipsychotics have been indicated for bipolar mania, bipolar depression, and irritability associated with autistic disorder. Antipsychotics are also used off label for psychotic or refractory depression; refractory anxiety disorders; and conditions associated with agitated or aggressive behaviors. Due to the severity and chronicity of severe mental disorders, the broad range of potential treatment targets, and the relative ease of use of second-generation antipsychotics (SGAs), which are associated with a lower risk of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD), prescribing rates have increased considerably over the last decade. With increased utilization of these medications comes a greater responsibility to appropriately recognize, monitor, and manage side-effect clusters that can adversely affect physical and mental outcomes.

[1]  C. Correll,et al.  One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review. , 2007, Journal of child and adolescent psychopharmacology.

[2]  C. Correll.  Balancing Efficacy and Safety in Treatment with Antipsychotics , 2007, CNS Spectrums.

[3]  Jonathan M. Meyer,et al.  Cardiovascular effects of antipsychotics , 2007, Expert review of neurotherapeutics.

[4]  S. Snyder,et al.  Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase , 2007, Proceedings of the National Academy of Sciences.

[5]  P. Lim,et al.  Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial , 2007, Schizophrenia Research.

[6]  Kiwon Lee,et al.  Hyperperfusion Syndromes: Insight into the Pathophysiology and Treatment of Hypertensive Encephalopathy , 2007, CNS Spectrums.

[7]  Craig W. Colton,et al.  Congruencies in Increased Mortality Rates, Years of Potential Life Lost, and Causes of Death Among Public Mental Health Clients in Eight States , 2006, Preventing chronic disease.

[8]  C. Correll.  Real-life switching strategies with second-generation antipsychotics. , 2006, The Journal of clinical psychiatry.

[9]  Andrew Farah,et al.  Atypicality of atypical antipsychotics. , 2005, Primary care companion to the Journal of clinical psychiatry.

[10]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[11]  R. Krauss,et al.  Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? , 2005, The American journal of cardiology.

[12]  R. Baldessarini,et al.  Modern antipsychotic drugs: a critical overview , 2005, Canadian Medical Association Journal.

[13]  P. Weiden,et al.  Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. , 2004, The American journal of psychiatry.

[14]  John M Davis,et al.  Physical health monitoring of patients with schizophrenia. , 2004, The American journal of psychiatry.

[15]  J. Racoosin,et al.  Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. , 2004, Diabetes care.

[16]  Del D. Miller.  Atypical antipsychotics: sleep, sedation, and efficacy. , 2004, Primary care companion to the Journal of clinical psychiatry.

[17]  C. Correll,et al.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. , 2004, The American journal of psychiatry.

[18]  S. Preskorn,et al.  2010 guide to psychiatric drug interactions , 2004 .

[19]  Paul Ernsberger,et al.  H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs , 2003, Neuropsychopharmacology.

[20]  Christian C. Felder,et al.  Muscarinic mechanisms of antipsychotic atypicality , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  S. Marder,et al.  Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials , 2003, Schizophrenia Research.

[22]  R. Mailman,et al.  Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology , 2003, Neuropsychopharmacology.

[23]  P. Buckley.  Broad therapeutic uses of atypical antipsychotic medications , 2001, Biological Psychiatry.

[24]  E. Richelson,et al.  Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. , 2000, Life sciences.

[25]  S. Potkin,et al.  Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder: A 6-Week Placebo-Controlled Trial , 1999, Neuropsychopharmacology.

[26]  Philip Seeman,et al.  Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine , 1996, Neuropsychopharmacology.

[27]  E. Richelson.  Neuroleptic Binding to Human Brain Receptors: Relation to Clinical Effects a , 1988, Annals of the New York Academy of Sciences.

[28]  E. Richelson,et al.  Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. , 1984, European journal of pharmacology.

[29]  C. Correll.  Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. , 2008, Journal of the American Academy of Child and Adolescent Psychiatry.

[30]  S. Preskorn,et al.  Guide to Psychiatric Drug Interactions , 2006 .

[31]  J. Newcomer.  Second-Generation (Atypical) Antipsychotics and Metabolic Effects , 2005, CNS drugs.

[32]  S. Laurent,et al.  Arterial Stiffness and Stroke in Hypertension , 2005, CNS drugs.

[33]  North American Association for the Study of Obesity , 1991, International journal of obesity.